Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other financing activities (2019 - 2021)

Harmony Biosciences Holdings' Other financing activities history spans 3 years, with the latest figure at $8.9 million for Q4 2021.

  • For Q4 2021, Other financing activities rose 52.96% year-over-year to $8.9 million; the TTM value through Dec 2023 reached $14.6 million, changed N/A, while the annual FY2023 figure was $3.0 million, N/A changed from the prior year.
  • Other financing activities for Q4 2021 was $8.9 million at Harmony Biosciences Holdings, up from $5.8 million in the prior quarter.
  • Across five years, Other financing activities topped out at $8.9 million in Q4 2021 and bottomed at $875000.0 in Q4 2019.
  • The 3-year median for Other financing activities is $5.8 million (2020), against an average of $5.3 million.
  • The largest annual shift saw Other financing activities skyrocketed 561.37% in 2020 before it surged 52.96% in 2021.
  • A 3-year view of Other financing activities shows it stood at $875000.0 in 2019, then surged by 561.37% to $5.8 million in 2020, then soared by 52.96% to $8.9 million in 2021.
  • Per Business Quant, the three most recent readings for HRMY's Other financing activities are $8.9 million (Q4 2021), $5.8 million (Q4 2020), and $5.8 million (Q1 2020).